Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: Recent U.S. military experience

Naomi E. Aronson; Glenn W. Wortmann; Steven C. Johnson; Joan E. Jackson; Robert A. Gasser; Alan J. Magill; Timothy P. Endy; Philip E. Coyne; Max Grogl; Paul M. Benson; Jeffrey S. Beard; John D. Tally; Jeffrey M. Gambel; Richard D. Kreutzer; Charles N. Oster

doi:10.1086/515027

Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: Recent U.S. military experience

Naomi E. Aronson^*, Glenn W. Wortmann, Steven C. Johnson, Joan E. Jackson, Robert A. Gasser, Alan J. Magill, Timothy P. Endy, Philip E. Coyne, Max Grogl, Paul M. Benson, Jeffrey S. Beard, John D. Tally, Jeffrey M. Gambel, Richard D. Kreutzer, Charles N. Oster

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

112 Scopus citations

Abstract

The efficacy and toxicity of sodium stibogluconate (SSG) at a dosage of 20 mg/(kg · d) for either 20 days (for cutaneous disease) or 28 days (for visceral, mucosal, or viscerotropic disease) in the treatment of leishmaniasis is reported. Ninety-six U.S. Department of Defense health care beneficiaries with parasitologically confirmed leishmaniasis were prospectively followed for 1 year. One patient was infected with human immunodeficiency virus; otherwise, comorbidity was absent. Clinical cure occurred in 91% of 83 cases of cutaneous disease and 93% of 13 cases of visceral/viscerotropic disease. Adverse effects were common and necessitated interruption of treatment in 28% of cases, but they were generally reversible. These included arthralgias and myalgias (58%), pancreatitis (97%), transaminitis (67%), headache (22%), hematologic suppression (44%), and rash (9%). No subsequent mucosal leishmaniasis was identified, and there were no deaths attributable to SSG or leishmaniasis.

Original language	English
Pages (from-to)	1457-1464
Number of pages	8
Journal	Clinical Infectious Diseases
Volume	27
Issue number	6
DOIs	https://doi.org/10.1086/515027
State	Published - Dec 1998
Externally published	Yes

Access to Document

10.1086/515027

Cite this

Aronson, N. E., Wortmann, G. W., Johnson, S. C., Jackson, J. E., Gasser, R. A., Magill, A. J., Endy, T. P., Coyne, P. E., Grogl, M., Benson, P. M., Beard, J. S., Tally, J. D., Gambel, J. M., Kreutzer, R. D., & Oster, C. N. (1998). Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: Recent U.S. military experience. Clinical Infectious Diseases, 27(6), 1457-1464. https://doi.org/10.1086/515027

@article{140e4837e43d42ddb7b60f9f83d9a0c4,

title = "Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: Recent U.S. military experience",

abstract = "The efficacy and toxicity of sodium stibogluconate (SSG) at a dosage of 20 mg/(kg · d) for either 20 days (for cutaneous disease) or 28 days (for visceral, mucosal, or viscerotropic disease) in the treatment of leishmaniasis is reported. Ninety-six U.S. Department of Defense health care beneficiaries with parasitologically confirmed leishmaniasis were prospectively followed for 1 year. One patient was infected with human immunodeficiency virus; otherwise, comorbidity was absent. Clinical cure occurred in 91% of 83 cases of cutaneous disease and 93% of 13 cases of visceral/viscerotropic disease. Adverse effects were common and necessitated interruption of treatment in 28% of cases, but they were generally reversible. These included arthralgias and myalgias (58%), pancreatitis (97%), transaminitis (67%), headache (22%), hematologic suppression (44%), and rash (9%). No subsequent mucosal leishmaniasis was identified, and there were no deaths attributable to SSG or leishmaniasis.",

author = "Aronson, {Naomi E.} and Wortmann, {Glenn W.} and Johnson, {Steven C.} and Jackson, {Joan E.} and Gasser, {Robert A.} and Magill, {Alan J.} and Endy, {Timothy P.} and Coyne, {Philip E.} and Max Grogl and Benson, {Paul M.} and Beard, {Jeffrey S.} and Tally, {John D.} and Gambel, {Jeffrey M.} and Kreutzer, {Richard D.} and Oster, {Charles N.}",

note = "Funding Information: Financial support: The U.S. Army Medical Materiel Development Activity provided the sodium stibogluconate and regulatory support. Dr. Kreutzer received financial support from the Walter Reed Army Institute of Research.",

year = "1998",

month = dec,

doi = "10.1086/515027",

language = "English",

volume = "27",

pages = "1457--1464",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "6",

}

Aronson, NE, Wortmann, GW, Johnson, SC, Jackson, JE, Gasser, RA, Magill, AJ, Endy, TP, Coyne, PE, Grogl, M, Benson, PM, Beard, JS, Tally, JD, Gambel, JM, Kreutzer, RD & Oster, CN 1998, 'Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: Recent U.S. military experience', Clinical Infectious Diseases, vol. 27, no. 6, pp. 1457-1464. https://doi.org/10.1086/515027

TY - JOUR

T1 - Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis

T2 - Recent U.S. military experience

AU - Aronson, Naomi E.

AU - Wortmann, Glenn W.

AU - Johnson, Steven C.

AU - Jackson, Joan E.

AU - Gasser, Robert A.

AU - Magill, Alan J.

AU - Endy, Timothy P.

AU - Coyne, Philip E.

AU - Grogl, Max

AU - Benson, Paul M.

AU - Beard, Jeffrey S.

AU - Tally, John D.

AU - Gambel, Jeffrey M.

AU - Kreutzer, Richard D.

AU - Oster, Charles N.

N1 - Funding Information: Financial support: The U.S. Army Medical Materiel Development Activity provided the sodium stibogluconate and regulatory support. Dr. Kreutzer received financial support from the Walter Reed Army Institute of Research.

PY - 1998/12

Y1 - 1998/12

N2 - The efficacy and toxicity of sodium stibogluconate (SSG) at a dosage of 20 mg/(kg · d) for either 20 days (for cutaneous disease) or 28 days (for visceral, mucosal, or viscerotropic disease) in the treatment of leishmaniasis is reported. Ninety-six U.S. Department of Defense health care beneficiaries with parasitologically confirmed leishmaniasis were prospectively followed for 1 year. One patient was infected with human immunodeficiency virus; otherwise, comorbidity was absent. Clinical cure occurred in 91% of 83 cases of cutaneous disease and 93% of 13 cases of visceral/viscerotropic disease. Adverse effects were common and necessitated interruption of treatment in 28% of cases, but they were generally reversible. These included arthralgias and myalgias (58%), pancreatitis (97%), transaminitis (67%), headache (22%), hematologic suppression (44%), and rash (9%). No subsequent mucosal leishmaniasis was identified, and there were no deaths attributable to SSG or leishmaniasis.

AB - The efficacy and toxicity of sodium stibogluconate (SSG) at a dosage of 20 mg/(kg · d) for either 20 days (for cutaneous disease) or 28 days (for visceral, mucosal, or viscerotropic disease) in the treatment of leishmaniasis is reported. Ninety-six U.S. Department of Defense health care beneficiaries with parasitologically confirmed leishmaniasis were prospectively followed for 1 year. One patient was infected with human immunodeficiency virus; otherwise, comorbidity was absent. Clinical cure occurred in 91% of 83 cases of cutaneous disease and 93% of 13 cases of visceral/viscerotropic disease. Adverse effects were common and necessitated interruption of treatment in 28% of cases, but they were generally reversible. These included arthralgias and myalgias (58%), pancreatitis (97%), transaminitis (67%), headache (22%), hematologic suppression (44%), and rash (9%). No subsequent mucosal leishmaniasis was identified, and there were no deaths attributable to SSG or leishmaniasis.

UR - http://www.scopus.com/inward/record.url?scp=0032450211&partnerID=8YFLogxK

U2 - 10.1086/515027

DO - 10.1086/515027

M3 - Article

C2 - 9868660

AN - SCOPUS:0032450211

SN - 1058-4838

VL - 27

SP - 1457

EP - 1464

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 6

ER -

Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: Recent U.S. military experience

Abstract

Access to Document

Fingerprint

Cite this